Fangzhou Inc. Reports Impressive Growth and Societal Impact in Internet Healthcare for 2024

In a world where technology often races ahead of our ability to keep up, Fangzhou Inc. is proving that innovation can directly translate into measurable success and societal impact.

The Hong Kong-based leader in Internet healthcare solutions has reported a robust year for 2024, with remarkable growth figures that stand as a testament to its strategic direction and execution.

Fangzhou’s financial results reveal a dazzling 11.2% increase in revenue, summing up to RMB 2.7 billion.

More dramatically, the company’s adjusted net profit soared by 139%, reaching RMB 17.2 million.

These figures aren’t just numbers on a balance sheet; they reflect the company’s adeptness at harnessing artificial intelligence to advance healthcare solutions, particularly in chronic disease management (CDM).

At the heart of this success is Fangzhou’s “AI Powered, Innovation-Driven Growth” mantra.

Dr. Xie Fangmin, the visionary founder, Chairman, and CEO, emphasized the company’s commitment to a patient-centric healthcare ecosystem.

“By aligning with national policies and harnessing the power of AI, we aim to build a dynamic, patient-centered ecosystem,” Dr. Xie stated, underscoring a mission that is both ambitious and pragmatic.

This approach has not only improved patient outcomes but has also bolstered user engagement.

As of December 31, 2024, the Jianke Platform boasted 49.2 million registered users, with average monthly active users climbing 20% year-on-year to 10.1 million.

These statistics highlight a growing, engaged community that trusts Fangzhou as a reliable partner in healthcare management.

Fangzhou’s strategy extends beyond user growth.

The company has made significant strides in expanding its physician network, which now includes 223,000 registered doctors, a majority of whom are affiliated with Class III hospitals.

This expansion is crucial in delivering high-quality care, particularly in underserved regions, thanks to initiatives like the sales force automation (SFA) system.

Moreover, Fangzhou’s advancements in its pharmaceutical supply chain are noteworthy.

Collaborations with over 1,500 suppliers and 900 pharmaceutical companies enable the platform to offer an extensive range of drug SKUs, meeting diverse patient needs.

But what does the future hold for Fangzhou?

The company is not resting on its laurels.

Looking ahead to 2025, it plans to deepen its market leadership in online chronic disease management.

The focus will be on enhancing AI capabilities, improving user experience, and optimizing supply chain operations.

Talent acquisition and development remain a priority, ensuring that Fangzhou retains its edge in a fast-evolving sector.

In an era where healthcare is increasingly digital, Fangzhou Inc. stands out as a beacon of what can be achieved when innovation meets execution.

As they continue to expand their capabilities and reach, one can only anticipate the further positive impact they will have on China’s healthcare landscape and beyond.

This is more than a business success story; it’s a narrative of transformation, powered by technology and driven by a commitment to positive societal change.